2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.
Landgren says that researchers and physicians in the field of myeloma are fortunate to have recently-approved treatments. Carfilzomib, a second-generation proteasome inhibitor, and pomalidomide, a third-generation immunomodulatory drug, are both oral agents and provide "hope and promise" for patients. Landgren anticipates the trend of developing oral drugs to continue.